Neumora Therapeutics Inc. Common Stock (NMRA)
Stock · NASDAQ · Health Care
$1.39as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta79.2%
BOLL Breakdown65.9%Resistance level
$1.58
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develop…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 63
- Website
- neumoratx.com/
Fundamentals
- 1-day range
- $1.38$1.51
- Market cap
- $303.87M
- P/E (trailing)
- —
- P/E (forward)
- -2.08
- EPS (trailing)
- $-1.33
- Dividend yield
- —
- Beta
- 2.81
- Avg. volume
- 1.90M
52-week range
$0.83015$3.65
Next earnings: November 5, 2026 · EPS estimate $-0.19
Forecasts
7 analyst ratings
Buy 80%
Hold 13%
Sell 7%
1-year price forecast
High
$14
+907.2%
Median
$5
+259.7%
Low
$3
+115.8%
Neumora Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NMRANeumora Therapeutics Inc. Common Stock$1.38▼ 6.76%Market cap $303.87MP/E —$0.83015$3.65
- SABSSAB Biotherapeutics Inc. Common Stock$3.79▼ 3.56%Market cap $289.80MP/E 26.94$1.85$5.15
- LCTXLineage Cell Therapeutics Inc. Common Stock$1.11▼ 4.31%Market cap $276.72MP/E —$1$2.09
- AVXLAnavex Life Sciences Corp. Common Stock$2.98▼ 4.79%Market cap $273.38MP/E —$2.26$10.4
- FENCFennec Pharmaceuticals Inc. Common Stock$12.19▲ 3.57%Market cap $334.56MP/E —$5.65$13.25
- PALIPalisade Bio Inc. Common Stock$2.01▼ 4.74%Market cap $336.74MP/E 3.25$0.53$2.86
- EDITEditas Medicine Inc. Common Stock$3.15▼ 4.55%Market cap $259.45MP/E —$1.66$4.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $1.38 | ▼ 6.76% | $0.83015$3.65 |
| SABS SAB Biotherapeutics Inc. Common Stock | $289.80M | 26.94 | $3.79 | ▼ 3.56% | $1.85$5.15 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $276.72M | — | $1.11 | ▼ 4.31% | $1$2.09 |
| AVXL Anavex Life Sciences Corp. Common Stock | $273.38M | — | $2.98 | ▼ 4.79% | $2.26$10.4 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $334.56M | — | $12.19 | ▲ 3.57% | $5.65$13.25 |
| PALI Palisade Bio Inc. Common Stock | $336.74M | 3.25 | $2.01 | ▼ 4.74% | $0.53$2.86 |
| EDIT Editas Medicine Inc. Common Stock | $259.45M | — | $3.15 | ▼ 4.55% | $1.66$4.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimatebenzinga · 8/14/2026
- Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) EstimateBenzinga · 8/14/2026
- Why Is BioAge Labs Stock Sinking Friday?Benzinga · 7/31/2026
Insider Activity
Insider Actions →Acquired
400.0K
Disposed
0
- Halawa Alaa · May 27, 2026 · Grant80.0K
- Maykin Ho · May 27, 2026 · Grant80.0K
- Piacquad David · May 27, 2026 · Grant80.0K
- Kristina Burow · May 27, 2026 · Grant80.0K
- Matthew K. Fust · May 27, 2026 · Grant80.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 71.23M
- Total value held
- $137.26M
- Institutional holders
- 109
Top holders this quarter
- Unknown8.50M
- Unknown6.09M
- Unknown5.10M
- Unknown4.46M
- Unknown3.89M
- Unknown3.50M
- Unknown3.31M
- Unknown2.75M
- Unknown2.56M
- Unknown2.12M
See the full, filterable feed with live charts on the MarketWall dashboard.